Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.33 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.33 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581038 | 0.88 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29581876 | 0.88 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL27100952 | 0.83 | ALDH1A1 (0.50) | CA12CA2CA3CA4CA6 | |
| SCHEMBL28091491 | 0.80 | TDP1 (0.45) | CA12CA2CA3CA4CA6 | |
| SCHEMBL25853689 | 0.79 | CA12 (0.33) | CA12CA2CA3CA4CA6 | |
| SCHEMBL30664066 | 0.78 | CA12 (0.50) | CA12CA2CA3CA4CA6 | |
| SCHEMBL16821921 | 0.78 | CA12 (0.50) | CA12CA2CA3CA4CA6 | |
| SCHEMBL4120760 | 0.77 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL13407589 | 0.77 | — | — | |
| SCHEMBL9284840 | 0.77 | TSHR (0.32) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| WO-2020024932-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-05 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014081946-A2 | METHODS FOR THE RECYCLING OF WIRE-SAW CUTTING FLUID | MEMC SINGAPORE PTE, LTD. (SG) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081960-A2 | SYSTEMS FOR THE RECYCLING OF WIRE-SAW CUTTING FLUID | MEMC SINGAPORE PTE, LTD. (SG) | 2014-05-30 | — | — | WO | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | CA12 4778/4885CA2 4689/4885CA3 4806/4885 |
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CA12 4722/4885CA2 1924/4885CA3 4419/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | CA12 4358/4885CA2 2268/4885CA3 4694/4885 |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CA12 4449/4885CA2 4260/4885CA3 4757/4885 |
| US-20170283398-A1 | 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB2, IGF1R | CA12 4478/4885CA2 2844/4885CA3 4605/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | CA12 4680/4885CA2 4584/4885CA3 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.